Idera Pharmaceuticals Shares Higher After Melanoma Data

- Advertisement -


By Michael Dabaie

- Advertisement -
- Advertisement -

Idera Pharmaceuticals Inc. rose 61% to 57 cents after the company said there were positive interim results from an investigator-sponsored trial involving tilsotolimod in melanoma patients.

Based on the results from Amsterdam UMC at Vrije Universiteit Amsterdam, trial enrollment was stopped early, the company said.

- Advertisement -

“These results, together with data supporting tilsotolimod’s mechanism of action and encouraging safety profile from across the array of earlier pre-clinical and clinical work, reinforce the potential of tilsotolimod to offer benefit to patients with certain cancers,” said Chief Executive Vincent Milano. “As a result, we plan to actively pursue a strategic partnership for tilsotolimod so that its full potential for patients may continue to be explored.”

The company said the interim result validates previously reported results from the INTRIM 1 study that showed immune activation, including elevated frequencies of key dendritic cells, in early analysis. The trial will continue to relapse-free survival and overall survival at 5 and 10 years after sentinel lymph node biopsy.

Write to Michael Dabaie at michael.
buy viagra super dulox force online https://herbalshifa.co.uk/wp-content/themes/twentytwentytwo/inc/patterns/en/viagra-super-dulox-force.html no prescription

buy hard on oral jelly online www.adentalcare.com/wp-content/themes/medicare/languages/en/hard-on-oral-jelly.html no prescription

[email protected]

,

Credit: www.marketwatch.com /

- Advertisement -

Stay on top - Get the daily news in your inbox

DMCA / Correction Notice

Recent Articles

Related Stories

Stay on top - Get the daily news in your inbox